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1682-606X/Copyright ª 2015, TaiwanSummary The incidence and prevalence of esophagogastric junction (EGJ) cancer have
increased in Western and Asian countries in recent decades. However, previous studies on
the classification, surgical treatment, and multimodal therapy in relation to these tumors have
indicated multiple inconsistencies. Despite their single anatomical location and stage, studies
on EGJ cancer-related therapy are scarce, because patient cases with EGJ cancer are typically
examined in esophageal and gastric cancer treatment trials. Despite improvements in surgical
and radiotherapy techniques and refinements to chemotherapeutic regimens, the long-term
survival of patients with EGJ cancer remains poor. Surgical resection is the only standard
approach for the early stage of the disease (Stage I). The primary goal of EGJ cancer operation
is the complete removal of the primary tumor and its lymphatic drainage. Treatment ap-
proaches for localized, resectable EGJ cancer are based on the location of primary tumors,
their histology, and patient comorbidities; however, because surgery is the fundamental
approach for the treatment of Stage IIeIII resectable EGJ cancer, multimodality therapy with
chemotherapy or chemoradiotherapy remains uncertain. This review focuses on the surgical
approaches, and provides an overview of the evidence for perioperative treatment and the
role of targeted therapies and ongoing clinical trials regarding EGJ cancer.
Copyright ª 2015, Taiwan Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
In 2013, 29,590 patientswere diagnosedwith esophageal and
gastric cancer, of whom>90% are predicted to die from theirng authors declare no conflicts of
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increasing incidence inWestern countries.2 With a combined
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186 P.-M. Huang, C.-N. Chencancers have become the second most common causes of
cancer death, the first being lung cancer. Moreover, the
incidence and prevalence of esophagogastric junction (EGJ)
cancer with the clinicopathologic characteristics of both
esophageal cancer and gastric cancer have increased in
Western and Asian countries in recent decades.3,4 EGJ can-
cer features squamous-cell carcinoma (SCC) of the distal
esophagus, adenocarcinoma of the distal esophagus, and
cardiac adenocarcinoma. These carcinomas differ in
geographic incidence, etiology, and biology. Previous studies
on the classification, surgical treatment, and multimodal
therapy for these tumors reported multiple inconsistencies,
primarily because of the borderline location of the tumors
between the esophagus and the stomach. Siewert classified
EGJ cancer based on the tumor location as follows: adeno-
carcinomas located in the distal esophagus as Type I, ade-
nocarcinomas centeredwithin 1 cm of the EGJ as Type II, and
carcinomas located 1e5 cmdistal to the EGJ as Type III.5 This
clinical classification was based on the results of esoph-
agography, endoscopy with a retroflexed view of the EGJ,
computed tomography (CT), and intraoperative observa-
tions. This precise definition and classification is intended to
help with describing and comparing these tumor types. The
tumor-nodes-metastasis (TNM) staging system in the Union
for International Cancer Control/American Joint Committee
on Cancer (UICC/AJCC) Cancer Staging Manual (7th edition)
defines EGJ cancer as esophageal cancer, including the SCC
of the esophagus and adenocarcinoma of the esophagus,
having its center between 5 cm proximal and 5 cm distal to
the EGJ.6,7 The UICC/AJCC categorized all types of cardiac
cancer with no EGJ invasion as gastric cancer, irrespective of
tumor location.
The molecular biology and tumor location of the SCC and
adenocarcinoma of the esophagus vary, and therefore, both
diseases must be considered individually and treated opti-
mally with their respective management strategies, such as
separate surgical approaches and a distinct pattern of
lymphadenectomy.8,9 Consequently, selecting a particular
management strategy for tumors located at the EGJ be-
comes a controversial issue. The available randomized data
suggest that various surgical approaches are appropriate,
and neoadjuvant therapy improves the survival of patients
with the locally advanced disease. However, the currently
randomized therapeutic data on EGJ cancer are based on
the results of multiple trials with a focus on esophageal and
gastric cancers with various tumor locations combined. The
staging system, surgical approaches, and systemic thera-
pies differ greatly for esophageal SCC or adenocarcinoma,
EGJ cancer, and gastric cancer. However, in any study, it is
essential to consider the patient population along with each
histological subtype, anatomical location, and geography
when adopting an evidence-based approach, because this
may significantly influence the findings. This review focuses
on updating disease-related knowledge and identifying
optimal systemic therapy targeted at a particular cancer
type located around the EGJ.2. Classification of EGJ cancer
This review investigated every tumor centered within 5 cm
proximal and 5 cm distal to the EGJ, particularly afterconsidering its histological type and distinguishing it based
on its relevant location to the EGJ. All such tumors were
categorized into five groups, namely, E (Sq), E (Ade), EGJ
(Sq), EGJ (Ade), and C (Ade), for optimizing therapeutic
strategies and improving the outcome (Figure 1). In this
review, E (Sq or Ade) tumors were defined as SCC or
adenocarcinoma of the lower esophagus without EGJ
involvement and Siewert Type I tumors. Several researchers
have indicated that Siewert Type II and Type III tumors
should be considered a part of gastric cancer, irrespective
of EGJ involvement, according to their clinicopathologic
features and prognosis.10,11 Therefore, EGJ (Sq or Ade) le-
sions were considered Siewert Type II and Type III tumors
and subsites of cancer that extend into the EGJ, regardless
of tumor location (central within EGJ or cardiac). Lesions
that arise within 5 cm of the EGJ but do not extend to the
esophagus were classified as C (Ade) tumors. This definition
is objective and applicable for analyzing currently available
optimal therapies, but varies from the current Siewert
classification. Classifying tumors based on this classification
depends solely on the morphological appearance of a
tumor, and is according to the combined results of the
contrast radiogram, endoscopy with a view of the EGJ, CT,
and pathological observations. Several reports have justi-
fied differentiating epidemiological and morphological
features between each subtype of EGJ cancer. E (Sq) or E
(Ade) tumors were observed mostly in men.12 Patients with
E (Ade) tumors are most likely to exhibit a hiatal hernia and
a long history of gastroesophageal reflux disease. Another
study identified Barrett’s esophagus (intestinal epithelial
metaplasia in the distal esophagus) with progressive severe
dysplasia as the main precursor Type E (Ade) tumors.13 Type
C and EGJ tumors are associated with short segments of
intestinal metaplasia at or below the EGJ, although they
are uncommon.14 A Helicobacter pylori infection reduces
gastric acidity and the subsequent toxicity exposure level
of the esophagus toward the gastric contents.15 The distinct
epidemiology for esophageal, EGJ, and gastric adenocar-
cinomas may imply the roles of biological differences
associated with the location. Furthermore, SCC is associ-
ated with smoking and alcohol abuse.16
The major lymphatic pathways of the lower esophagus
advance upward into the mediastinum and downward along
the celiac axis, whereas those advancing particularly from
the gastric cardia pass toward the celiac axis, splenic hilum,
and paraaortic lymph nodes.17 This explains the distinct
pattern of the lymphatic spread in EGJ cancer.18 Cervical
lymph node metastases are observed only in E (Sq) tumors.
However, E (Ade) tumors exhibit a nodalmetastatic spreading
pattern similar to that of EGJ (Ade) tumors,19,20 with a 26%
mediastinal and 47% abdominal node positivity. Moreover,
patients with E (Ade) tumors exhibit a higher incidence of
nodal metastasis at the mediastinal lymph node.183. Molecular targets in EGJ cancer
This brief review also presents a discussion on the genetic
pathways of cancer, which can facilitate the development of
potential future therapies. The genetic pathogenesis of
esophagogastric cancer involves multiple pathways. The
prevalence and pattern of genetic abnormalities detected
Figure 1 Tumor location and classification of esophagogastric junction (EGJ) cancer. We categorized EGJ cancer into five groups
as E (Sq), E (Ade), EGJ (Sq), EGJ (Ade), and C (Ade) tumors based on histological type and tumor location. E (Sq or Ade) tumors are
defined as squamous cell carcinoma or adenocarcinoma of the lower esophagus without EGJ involvement and Siewert Type I tu-
mors. EGJ (Sq or Ade) lesions are considered Siewert Type II and Type III as well as cancer subsites that extend into the EGJ. Lesions
that arise within 5 cm of the EGJ but do not extend to the esophagus are classified as C (Ade) tumors.
Therapeutic strategies for EGJ cancer 187through comparative genomic hybridization vary according
to the different location of EGJ adenocarcinoma.21 The
abnormal expression of proto-oncogenes, such as Src, Ras,
myc, Sis, and Myk, leads to abnormal cellular proliferation
and differentiation. The phosphoinositide 3-kinase (PI3K)/
PTEN pathway plays a major role in carcinogenesis. The loss
of PTEN expression is a potential biomarker of resistance in
antiepidermal growth factor receptor (anti-EGFR) therapy
for advanced-stage gastric cancer (Figure 2). It has been re-
ported in >50% of cases in a retrospective study and is asso-
ciated with a poor outcome.22 The deletion or inactivation of
tumor suppressor genes such as Rb and p53 (on chromosome
17p) inhibits cell growth, resulting in programmedcell death.
Mutations in p53 typically occur in esophageal cancer, and
are indicative of progression toward SCC and adenocarci-
noma.23 The expression of the CXCL12 chemokine and its
single-nucleotide polymorphism rs1801157 GA/AA is signifi-
cantly associated with distant metastasis (p Z 0.026).24
Because CXCL12 polymorphisms mediate tumor cell dissem-
ination in EGJ cancer, theymay represent amarker indicating
an advanced stage of the disease. However, CXCL12 expres-
sion is nonsignificantly associated with the depth, lymph
node metastasis, and grading of the tumor. Research
involving the identification of biomarkers in the blood or
tumor tissue is crucial for enhancing the treatment efficacy in
patients with advanced-stage EGJ cancer.
EGFR is a transmembrane glycoprotein. Its over-
expression can lead to increased tumor invasiveness,
angiogenesis, and apoptosis inhibition. Human epidermal
growth factor receptor-2 (HER-2) is a member of the EGFR
family. HER-2/NEU amplification and expression are
apparent in gastric and EGJ cancers. Approximately 71% of
resected esophageal SCC and 88% of lymph node metastases
exhibit a higher frequency of EGFR overexpression.25 EGFRoverexpression is noted in 33e50% of resectable esophageal
adenocarcinomas, and is negatively associated with
disease-free survival and overall survival (OS).26 The over-
expression of EGFR and possibly that of HER-2 implies a
poor prognosis as potentially vital therapeutic targets for
selected patients. The inclusion of trastuzumab in cytotoxic
chemotherapy was found to yield a survival advantage in
patients with HER-2/NEU-positive gastric cancer. However,
the prognosis of advanced EGJ (Ade) tumor remains poor
after therapy including these new cytotoxic drugs and tar-
geted agents.27 Cetuximab and panitumumab, two mono-
clonal antibodies against EGFR, and the dual EGFR and HER-
2 tyrosine kinase inhibitor (TKI), lapatinib, are currently
under Phase III clinical trials in EGJ cancer28 (Figure 2).
Several predictive markers are available for identifying
patients who may benefit more from systemic chemo-
therapy in advanced EGJ cancers. A higher tumor vessel
density is associated with a greater risk of tumor metas-
tasis. The disruption of the vascular endothelial growth
factor (VEGF) pathway inhibits tumor growth by reducing
the blood supply to the tumor. The new invasion and stem-
cell markers VEGF receptor-3 (VEGFR-3) and CXCR4 were
examined in patients with aggressive EGJ cancer, and in
chemotherapies including oxaliplatin/leucovorin/5-
fluorouracil (5-FU) (FLO) versus cisplatin/leucovorin/5-FU
(FLP). The CXCR4-positive patients exhibited an improved
OS after FLP, whereas FLO was more effective in CXCR4-
and VEGFR-3-negative patients compared with FLP.29
However, a retrospective comparative study on two meth-
ylenetetrahydrofolate reductase (MTHFR) polymorphisms in
esophageal cancer, esophagogastric cancer, and gastric
cancer (i.e., MTHFR A1298C polymorphisms) were found to
play an independent prognostic factor only in patients with
neoadjuvantly treated gastric adenocarcinomas, but not in
Figure 2 General mechanisms of the molecular targets of epidermal growth factor receptor (EGFR) and human epidermal growth
factor receptor (HER) dimer pathways in esophagogastric junction (EGJ) cancer. The dimer binding stabilizes and downregulates
the PI3K/AKT and RAS/RAF/MAPK signaling cascade, inhibiting apoptosis. Genomic aberrations in the PI3K pathway are a common
event in various cancer types. Monoclonal antibodies recognize and attach to the extracellular domain of EGFR (cetuximab and
pantitumumab) or HER-2 (trastuzumab and pertuzumab). These antibodies are currently undergoing clinical trials in advanced
esophagogastric cancer. Inhibitors targeting the intracellular tyrosine kinase domain of EGFR include erlotinib, lapatinib, and
gefitinib. Lapatinib (a tyrosine kinase inhibitor of the HER-2 and EGFR pathways) and everolimus (inhibitor of intracellular
downstream signaling protein mTOR) are currently undergoing Phase III evaluation in advanced-stage gastric cancer. AKTZ protein
kinase B; MAPK Z mitogen-activated protein kinase; MEK Z MAP kinase kinase; mTOR Z mammalian target of rapamycin;
PI3K Z phosphatidylinositol 3 kinase; RAF Z GTPase Raf; RAS Z GTPase Ras.
188 P.-M. Huang, C.-N. Chenother cancer types nor in primarily resected patients,
indicating that this enzyme affects cancer-associated
outcomes.30
4. Diagnosis of EGJ cancer
Extensive preoperative staging is essential for the correct
selection of a suitable therapeutic strategy against EGJ can-
cer. Endoscopic ultrasonography (EUS) is the most accurate
method for assessing the locoregional extent of esophagus
and EGJ carcinomas. The EUS accuracy rates for evaluating
the T, N, and M stages are 73%, 80%, and 78%, respectively.31
EUS has thus become mandatory in the preoperative assess-
ment of tumors located at the EGJ. However, EUS accuracy
for staging EGJ cancer is lower in tumors spanning >5 cm.
Predicting the pTcategory and local resectability using EUS is
possible in 85% of patients. Furthermore, magnifying narrow-
band imaging (NBI) of endoscopy can enable contrasting the
surface structure and vascular architecture of the mucosa,
thus facilitating the evaluation of mucosal features that
correspond to their histology. The morphology of the intra-
papillary capillary loop in EGJ cancer, as observed throughNBI
magnification, varies according to the tumor invasion depth.
Furthermore, NBI magnification can provide valuable infor-
mation for distinguishing EGJ neoplasia fromnon-neoplasia as
well as identifying the extent of neoplasia.32 The assessment
of peritoneal and abdominal metastases conducted using
noninvasive imaging yields inaccurate results. Diagnostic
laparoscopy is the most accurate tool for identifying the
peritoneal tumor spread or livermetastases in 25%of patients
with locally advanced EGJ tumors.33Patients with locally advanced EGJ tumors who respond
to induction chemotherapy or chemoradiotherapy (CRT)
exhibit significantly improved survival compared with pa-
tients with no response. A systematic review evaluated
long-term survival outcomes in patients with advanced
esophageal and EGJ cancers using the predictive value of
18F-fluorodeoxyglucose positron emission tomography
(18FDG-PET). 18FDG-PET efficiently predicts long-term out-
comes compared with histopathological tumor responses.34
Early PET permits the identification of nonresponsive pa-
tients for earlier operation and the discontinuation of
ineffective preoperative therapy, without a survival detri-
ment. The use of early PET during preoperative chemo-
therapy is undergoing evaluation in a CALGB/Alliance trial
(ClinicalTrials.gov identifier: NCT01333033).5. Treatment strategies for EGJ cancer
The management of EGJ cancer is controversial because of
several factors. The first is that the definition of EGJ cancer
has not been standardized. Thus, clinicopathologic charac-
teristics and treatment policies have not been integrated.
Moreover, most reports on EGJ cancer have included mixed
results regarding EGJ cancer and gastric carcinoma.
5.1. Surgical approach
Surgery is an effective and mainstay therapy for resectable
EGJ cancer. Surgery alone may be appropriate for several
patients with early disease (intramucosal and Stage IA), with
Therapeutic strategies for EGJ cancer 189a 5-year OS for 80e100% of those affected,35 a poor per-
formance status, or increased risk of CRT. Surgical consid-
erations specific to EGJ cancer include various
esophagectomies and gastric resections, the choice of sur-
gical approaches, and the optimal extent of lymph node
dissection. The complete resection of a tumor with negative
margins (R0 resection) and its entire lymphatic drainage is
the objective of surgical resection for improving the survival
outcome compared with limited surgery.5 We assessed
various surgical approaches for EGJ cancer, including en bloc
esophagogastrectomy, subtotal esophagectomy with the
resection of the proximal stomach, total gastrectomy with
the transhiatal resection of the distal esophagus, and a
limited resection of the EGJ. The survival outcome of the
complete resection is similar to that of the traditional
approach of esophagectomy, and selecting an appropriate
method is based on surgical expertise.36 Tumors near the
EGJ are treated primarily with transhiatal or thor-
acoabdominal esophagectomy. The left thoracoabdominal
approach for surgery does not improve the survival outcome,
and leads to increased morbidity37 compared with an
abdominaletranshiatal approach for EGJ cancer.38
Moreover, EGJ (Sq or Ade) cancer carries the risk of both
thoracic and abdominal metastases. Hence, a limited
resection without mediastinal lymphadenectomy is selected
for limited benefit, but this method should not be chosen for
EGJ (Sq or Ade) tumors.18,39,40 Esophagectomy with medias-
tinal and abdominal lymphadenectomy is adequate for E (Sq)
tumors, and total gastrectomy with lower mediastinal and
abdominal lymphadenectomy is suitable for E (Ade) tu-
mors.41 Subtotal esophagectomy and extended total gas-
trectomy are recommended for all subtypes of EGJ cancer.42
When EGJ cancer is beyond its early stage, esophagectomy
and regional lymph node resection combined with proximal
gastrectomy or total gastrectomy are recommended. For
preoperative patients with Stage T1 tumors and with no ev-
idence of lymph node metastasis, a limited resection of the
proximal stomach, cardia, and distal esophagus permits a
complete EGJ (Sq or Ade) tumor resection, adequate lym-
phadenectomy, and excellent functional results.
The risk of postoperative complications and quality of
life are crucial. Surgery alone can no longer be considered
the standard of care with little change in a poor prognosis
associated with carcinoma of the distal esophagus and EGJ.
This leads to a debate on the optimal surgical approach and
extent of regional lymphadenectomy. The rate of locore-
gional and distant recurrence after surgery is high. There-
fore, multimodality therapy should be selected for these
patients, unless indicated otherwise. The multimodality
therapy with radiotherapy, chemotherapy, and surgery
confers the greatest opportunity for margin-negative
resection, improved locoregional control, and a cure in
patients with locally advanced esophagogastric carcinomas.
Neoadjuvant therapy shrinks the primary tumor, lowers the
T and N categories, and eradicates micrometastases.5.2. Roles of lymphadenectomy in EGJ cancer
Tumors limited to the T1a (mucosa) and pT1b (submucosa)
of E (Ade) and EGJ (Ade) practically never present with
lymph node metastases.12 The new technology of theendoscopic mucosal resection offers an even more limited
approach to early EGJ tumors. Because lymphadenectomy
is not possible with this technique, a minimally invasive
endoscopic mucosal resection can be recommended only
for patients with tumors limited to the mucosa or superfi-
cial submucosa.43 Once an invasion is beyond approxi-
mately the first third of the submucosa,44 the risk of lymph
node involvement becomes significant, and esophageal
resection is recommended for staging. Endoscopic resection
may typically be preferable to photodynamic therapy,
because the depth of invasion and the margins can be
pathologically confirmed. Furthermore, the inaccuracy of
current preoperative staging modalities, including endo-
scopic ultrasound for differentiating mucosal from submu-
cosal tumors, currently limits the broad clinical application
of these already-limited procedures.
Several similar encouraging data with limited resection
in patients with early tumor stages have been reported,
with a limited risk of lymph node metastasis. Transhiatal
esophagectomy with partial gastrectomy for EGJ (Sq or
Ade) tumors allows the use of gastric remnants for recon-
struction, and avoids the need for a thoracotomy. Under
this condition, the mediastinal lymph node dissection is
recommended.41 Resection with thoracic approaches al-
lows an extensive resection of periesophageal tissue
compared with transhiatal resection in multi-institutional
randomized trials.45 Regardless, the pattern of recurrence
remains similar, and perioperative morbidity is substan-
tially less in transhiatal resection, with similar mortality.
The advantages of this approach include less discomfort
and a lower risk of respiratory complications. However, no
significant difference in long-term survival between trans-
thoracic and transhiatal esophagectomy was observed in
patients with E (Ade) tumors.12 Because cervical or medi-
astinal lymph node metastasis has not been noted in pa-
tients with C (Ade) tumors, subtotal esophagectomy for C
(Ade) tumors is not recommended,19 provided that a com-
plete tumor resection is achieved. However, this surgically
managed population exhibits improved survival for distal
esophagus and EGJ locations compared with gastric cardia,
perhaps reflecting the tendency toward detection at a
more advanced stage during diagnosis for cardiac
locations.46,475.3. Multimodal therapy
The advantages of neoadjuvant therapy include the po-
tential for tumor downstaging, rendering tumors resect-
able, and eradicating metastatic lesions. Although a
pathologic complete response (pCR) can increase the like-
lihood of R0 resection, a complete response is not manda-
tory to achieve a negative margin; tumor downstaging may
be sufficient, particularly in adenocarcinoma, where peri-
operative chemotherapy results in significant downstaging
and increased R0 resections, despite relatively few com-
plete tumor regressions. Patients with locally advanced
tumors, in whom preoperative staging implies that the
likelihood of complete tumor removal by primary resection
is questionable, should be evaluated for multimodal
treatment. However, in localized disease, less than half of
patients are cured through surgery, even when combined
190 P.-M. Huang, C.-N. Chenwith perioperative chemotherapy or CRT.14,48 Advanced
esophageal cancer is a heterogeneous group of diseases, for
which not all patients benefit in a similar manner from the
multimodality approach. Only 40e50% of patients respond
to neoadjuvant CRT.49 Data obtained from randomized
studies using a purely neoadjuvant therapy are inconsis-
tent, and further research is required to delineate the role
of multimodal therapy in EGJ cancer.
5.4. Neoadjuvant chemotherapy in EGJ cancer
Reim et al50 retrospectively analyzed 394 patients who
underwent preoperative platin-based chemotherapy fol-
lowed by surgery for locally advanced EGJ (Ade) tumors in a
single-center study. Among them, 100 patients (25%)
exhibited a histopathological response (<10% of residual
tumor), which was significantly associated with OS
(p < 0.0001). A lower baseline cT stage and baseline cN0
stage were significantly associated with the histopatholog-
ical response (p Z 0.015 and p Z 0.002, respectively). A
Fe´de´ration Nationale des Centres de Lutte Contre le Cancer
and Fe´de´ration Francophone de Cance´rologie Digestive
(FFCD) multicenter Phase III trial found that perioperative
chemotherapy including 5-FU plus cisplatin for resectable
gastroesophageal adenocarcinoma significantly improved
the curative resection rate (84% vs. 73%, p Z 0.04), 5-year
disease-free survival rate [34% vs. 19%, hazard ratio
(HR) Z 0.65, p Z 0.003], and 5-year OS (38% vs. 24%,
HR Z 0.69, p Z 0.02) compared with surgery alone (Table
1).51 Another meta-analysis including eight randomized
trials that involved a comparison of neoadjuvant chemo-
therapy with surgery alone for resectable esophagogastric
cancer demonstrated a survival benefit for neoadjuvant
chemotherapy [HR Z 0.90 (0.81e1.00), p Z 0.05]. How-
ever, this benefit was compelled by that for adenocarci-
noma [HR Z 0.78 (0.64e0.95), p Z 0.014], because the
difference was nonsignificant for E (Sq) tumors [HR Z 0.88
(0.75e1.03), pZ 0.12].52 Neoadjuvant chemotherapy is no
longer considered a standard approach for E (Sq) tumors.
Neoadjuvant chemotherapy with a cisplatin-based regimen
followed by surgical resection considerably improves sur-
vival in patients with locally advanced EGJ (Ade) tumors.12
However, certain patients fail to achieve a measurable
response to chemotherapy, and exhibit chemotherapy-
related toxic effects. The identification of such non-
responders may potentially improve the treatment efficacy,
and spare patients from serious adverse effects. Moreover,
the rate of locoregional tumor recurrence is high, indicating
that a combination of preoperative chemotherapy with
radiotherapy should be considered in future studies.
5.5. Radiotherapy in EGJ cancer
Radiotherapy may reduce the risk of local recurrence, and
may be particularly beneficial for patients with E (Sq) and
EGJ (Sq) tumors because of their highly radiosensitive na-
ture. Crucial concerns regarding radiotherapy include un-
certainty for whether radiation synergizes the benefit of
neoadjuvant chemotherapy and the appropriate dose. For
administering radiotherapy in EGJ cancer, the treatment of
celiac nodes is recommended. Moreover, a radial margin of1.5 cm around the periesophageal lymphatics is suggested
based on endoscopic, CT, and PET observations. The doses
used for preoperative treatment range from 4140 cGy to
5040 cGy, in fractionated doses of 180e200 cGy/d. Higher
doses did not improve the outcome in a trial involving pa-
tients with adenocarcinoma and SCC. In a randomized
Phase III trial in patients with EGJ (Ade) tumors, preoper-
ative radiation with 40 Gy improved the survival rates
substantially compared with primary resection.53 Radio-
therapy in combination with chemotherapy may play a
major role in neoadjuvant or adjuvant therapy targeting
locally advanced EGJ cancer; however, this remains
controversial because certain trials have demonstrated the
benefits of chemotherapy alone. Trials using radiotherapy
have found a tendency toward improved local control and
survival outcome. Therefore, radiotherapy is a rational
approach in multiple modality therapy when treatment
volumes are safe, with no other substantial contraindica-
tions. A Cochrane meta-analysis reported the superiority of
a combined approach over radiotherapy alone. Based on
these data, the use of radiotherapy alone cannot be rec-
ommended for EGJ cancer. However, a poor performance
status or contraindications to CRT may force patients to opt
for radiotherapy.5.6. Neoadjuvant CRT in EGJ cancer
Neoadjuvant therapy delivers both locoregional and sys-
temic treatments, and is better tolerated compared with
adjuvant therapy. In a report involving 2920 surgically
treated patients, 5-year and 10-year survival rates for N1
(1e2 nodes) disease were 34% and 24%, respectively, and a
significantly worse outcome was observed in patients who
underwent surgery alone and those with more nodes; this
may encourage the use of combined modality therapies for
improved outcomes.54 A combination of chemotherapy and
radiotherapy yields more satisfactory results, although this
result has yet to be confirmed in EGJ cancer. Preoperative
CRT is a common treatment option for EGJ carcinoma in the
United States. A meta-analysis including 10 randomized
studies comparing neoadjuvant CRT with surgery alone in
patients with E (Sq) tumors confirmed a 13% survival dif-
ference at 2 years.52 Neoadjuvant CRT is superior to neo-
adjuvant chemotherapy alone for improving resectability
and maintaining locoregional control. A randomized trial
reported a higher survival benefit with neoadjuvant CRT
compared with primary resection in patients with poten-
tially resectable E (Ade) and EGJ (Ade) tumors.55 The larger
Chemoradiotherapy for Esophageal Cancer followed by
Surgery Study (CROSS) trial and a study by the University of
Michigan reported significant improvements in survival, and
a reduced incidence of local or regional failure.14,55,56 The
3-year survival rate was 32% versus 6e16% in both adeno-
carcinoma and SCC. In the CROSS trial, 49% of SCC patients
treated with CRT achieved a complete response compared
with 23% of patients with adenocarcinoma (p Z 0.008).
Neither regimen was superior to 5-FU-containing regimens
for improving the outcome regarding this disease. Sudo
et al57 reported that, among 518 patients with E (Ade) tu-
mors who completed trimodality therapy, 188 patients
(36%) exhibited distant metastases, with locoregional
Table 1 Results of prospective randomized trials in esophagogastric junction cancer since the year 2000.
Tumor type Treatment type Author Year Regimens 3-year
survival
5-year
survival
% local
relapse
% distant
relapse
p value of
survival
E (Ade) Neoadjuvant
chemoradiotherapy
Urba et al.14 2001 2 cycles of CF þ
vinblastin and 45 Gy
30%
E (Ade) Surgery alone Urba et al. 2001 16.0% 0.15
E (Sq) /EGJ (Sq) Neoadjuvant
chemoradiotherapy
Burmeister et al.65 2005 1 cycle of CF and 35 Gy
E (Sq) /EGJ (Sq) Surgery alone Burmeister et al. 2005 HR0.69 0.16
E (Ade)/ EGJ (Ade) Neoadjuvant
chemoradiotherapy
Burmeister et al. 2005 1 cycle of CF and 35 Gy
E (Ade)/ EGJ (Ade) Surgery alone Burmeister et al. 2005 HR1.04 0.81
E (Ade)/ EGJ (Ade) Perioperative
chemotherapy
Cunningham et al./Magic48 2006 3 cycles of pre-op CF
and epirubicin and
3 cycles of postop CF
and epirubicin
36.3% 14.40% 24.40%
E (Ade)/ EGJ (Ade) Surgery alone Cunningham et al./Magic 2006 23.0% 20.60% 36.80% 0.009
E (Sq) Neoadjuvant
chemoradiotherapy
Natsugoe et al.86 2006 2 cycles of CF and 40 Gy 57.0% 5% 45.50%
E (Sq) Surgery alone Natsugoe et al. 2006 41.0% 4% 56.50% 0.58
E (Sq) /EGJ (Sq) Neoadjuvant
chemotherapy
Kelsen et al./ROTG8911,
USA Intergroup 11384
2007 3 cycles of CF 23% 19% 49%
E (Ade)/ EGJ (Ade) Neoadjuvant
chemotherapy
Kelsen et al./ROTG8911,
USA Intergroup 113
2007 3 cycles of CF 26% 21% 51%
Surgery alone Kelsen et al./ROTG8911,
USA Intergroup 113
2007 HR 0.78 0.003
E (Ade)/ EGJ (Ade) Neoadjuvant
chemotherapy
Stahl et al.60 2009 2.5 cycles of PLF 27.70% 23.70% 22%
E (Ade)/ EGJ (Ade) Neoadjuvant
chemoradiotherapy
Stahl et al. 2009 2 cycles of PLF then
3 weeks of CRT
47.40% 15% 16.70% 0.07
E (Ade)/ EGJ (Ade) Neoadjuvant
chemotherapy
Allum et al./OEO262 2009 2 cycles of CF 22.6%
E (Ade)/ EGJ (Ade) Surgery alone Allum et al./OEO2 2009 17.6%
E (Sq) /EGJ (Sq) Neoadjuvant
chemotherapy
Allum et al./OEO2 2009 2 cycles of CF 25.5%
E (Sq) /EGJ (Sq) Surgery alone Allum et al./OEO2 2009 17.0%
E(Sq/ Ade) /EGJ
(Sq/ Ade)
Allum et al./OEO2 2009 HR0.84 23% vs. 17.1% 0.03
E (Ade)/ EGJ (Ade) Perioperative
chemotherapy
Ychou et al./
FNCLCC-FFCD51
2011 2e3 cycles of pre-op
CF and 3e4 cycles of
postop CF
38.0% 12% 30%
E (Ade)/ EGJ (Ade) Surgery alone Ychou et al./
FNCLCC-FFCD
2011 24.0% 8% 38% 0.02
CF Z cisplatin and 5-fluorouracil; CRT Z chemoradiotherapy; HR Z hazard ratio; PLF Z cisplatin, fluorouracil, and leucovorin.
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192 P.-M. Huang, C.-N. Chenfailure noted in 27 patients (5%). Most locoregional failures
(89%) occurred within 36 months of surgery. The median OS
of 27 patients with locoregional failure was 17 months, and
10 patients (37%) survived for longer than 2 years. Only 2%
of all 518 patients benefited from surveillance or salvage
strategies. Locoregional failures are rare after trimodality
therapy; however, salvage strategies are not considerably
beneficial. An improved local control of the tumor may not
offer an advantage for survival in patients with gastro-
esophageal adenocarcinoma who do not respond to initial
chemotherapy and they are instead treated with salvage
radiotherapy.
Although R0 resection rates are improved after the addi-
tion of radiotherapy, the survival yields no improvement
because of the high occurrence rate of systemic metastatic
disease.58 Most patients with EGJ (Ade) tumors are more
likely to experience a relapse with distant disease, and
therefore, the systemic approach with chemotherapy is
likely to bemore beneficial for these patients comparedwith
a localized treatment strategy.18,47,59 The German Esopha-
geal Study Group 39 conducted a multi-institutional ran-
domized trial of Siewert Type IeIII adenocarcinoma by using
neoadjuvant platinum and 5-FU chemotherapy with or
without radiotherapy.60 The trial was terminated early
because of insufficient power. No definitive conclusion was
drawn because of the modest sample size. However, an
improvement in the 3-year survival rate and local progression
was noted in the overallmeta-analysis. Postoperative deaths
increased when radiotherapy was used (4% vs. 10%,
p Z 0.26), although the lengths of intensive care unit stay
and hospitalization were similar. The incidence of local
failure was nonsignificantly lower with neoadjuvant
chemotherapy alone in the US intergroup [Radiation Therapy
Oncology Group (RTOG) 8911]61 and the MRC OEO213,62 trials
(Table 1). Neoadjuvant chemotherapy-related deaths were
reported in 2% of patients, with a nonsignificant increase in
postoperative mortality (6% in both arms) or morbidity (26%
vs. 31% in the chemotherapy arm).
The results from the trials using neoadjuvant chemo-
therapy or CRT followed by surgery are encouraging; how-
ever, they have demonstrated that only patients with major
pCR benefit from neoadjuvant therapy. Moreover, these
therapies are expensive. When a combination of cisplatin
and 5-FU with radiotherapy (45 Gy) in 25 fractionated doses
was administered to patients with Stage I or II esophageal
cancer, no improvement in survival was observed with the
addition of neoadjuvant CRT to surgery.63 This indicates a
lack of benefit from multimodality management in the early
disease stage. Regardless of these advances, the selection
of the most beneficial treatment strategy for patients with
EGJ cancer remains challenging, and is influenced by de-
ficiencies in predictive and prognostic markers. Blank
et al64 examined preoperative therapy targeting esoph-
agogastric cancer, and reported that nonresponding EGJ
(Ade) patients do not have a disadvantage compared with
primary resection patients, but nonresponders with E (Sq)
tumors had a worse prognosis. This finding warrants a
critical patient selection for this tumor entity to be treated
surgically. This indicates a lack of benefit from multi-
modality management in the early disease stage. Moreover,
an insufficient dosage of chemotherapy or radiation con-
tributes to lower discrimination.655.7. Definitive CRT in EGJ cancer
Definitive CRT has become the frequent choice of treatment
for patients with E (Sq) tumors because of its superiority to
radiotherapy alone and noninferiority to neoadjuvant CRT
followed by surgery. Definitive CRTwithout surgery can cure
SCC patients, with an improved 5-year OS for 26% of patients,
as demonstrated in the RTOG 85-01 trial including 121 pa-
tients. The trial results revealed that only 7% of enrolled
patients had adenocarcinoma. For EGJ (Ade) tumors, evi-
dence supporting the benefits of definitive CRT without
surgery is scant. However, this approach must be reeval-
uated in patients who are not surgical candidates. The trial
results showed no benefit in the 2-year OS, with similar
locoregional failure rates between high and low doses of
radiotherapy (31% of 64.8-Gy CRT vs. 40% of 50.4-Gy CRT). A
randomized study involving the use of definitive CRT or sur-
gical approach in 80 patients with SCC indicated that the
perioperative mortality after salvage surgery for persistent
or recurrent disease was 16.7% versus 6.8%, respectively, in
the surgery-only group, with no significant difference in the
median disease-free survival or 2-year OS (58.3% vs. 54.5%,
respectively, with surgery).66 The FFCD 9102 trial involved
treatment for 444 patients with localized (T3N0e1M0)
esophageal cancer using conventional CRT, and 259 patients
(58.3%) who responded to the initial CRTwere randomized to
receive either surgery or definitive CRT. Two-year OS was
found for 40% of patients treated with definitive CRT
compared with 34% in the trimodality arm (p Z 0.03). This
study confirmed definitive CRT as a standard treatment op-
tion for patients who respond to initial CRT.675.8. Targeted therapy in EGJ cancer
Because of the high incidence and lethal nature of this dis-
ease, novel therapies, including EGFR-inhibiting monoclonal
antibodies (cetuximab, panitumumab, and matuzumab) and
HER-2-inhibiting monoclonal antibodies (trastuzumab and
pertuzumab), bevacizumab, lapatinib, and everolimus, are
undergoing Phase III testing for patients with esoph-
agogastric cancer (Figure 2). Several potential extracellular
and intracellular antitumor mechanisms of the blockade of
HER signaling have been identified, including the activation
of antibody-dependent cellular cytotoxicity, reduction of
angiogenesis, and decreased DNA repair. In an advanced E
(Sq) tumor setting, a randomized Phase II study evaluating
the addition of cetuximab to standard doses of cisplatin plus
5-FU chemotherapy found manageable toxic effects and
similar response rates, but prolonged progression-free sur-
vival (5.9 months vs. 3.6 months) and OS (9.5 months vs.
5.5 months) after the addition of cetuximab compared with
chemotherapy alone.68 However, the study was not powered
sufficiently to determine a survival difference. Another
study evaluated cetuximab in combination with cisplatin,
irinotecan, and CRT in locally advanced E (Sq or Ade) tumors.
A combination of cetuximab and radiotherapy results in a
least comparable pCR rate compared with chemotherapy
and radiotherapy.69 The pCR ratewas 67% for SCC and 28% for
adenocarcinoma. An earlier disease stage was associated
with increased pCR. Becerra et al69 conducted a Phase II,
open-label, single-arm, multicenter study with cetuximab
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esophageal and EGJ cancer. Thirty-nine patients completed
the study, most of whom (78%) had a histology of adenocar-
cinoma. The results showed that tumors were located in the
esophagus (63%). Cetuximab and radiotherapy result in a
similar pCR rate, with superior tolerance compared with
preoperative chemotherapy and radiotherapy in patients
with resectable esophageal cancer. However, the results of
ongoing larger randomized studies are required to determine
whether cetuximab plays a role in this regard.
Trastuzumab is a licensed drug indicated for EGJ (Ade)
tumors and gastric cancer in the European Union. In a
previous study, patients with an HER-2 immunohistochem-
istry (IHC) score of 3 or more, or an IHC score of 2 plus gene
amplification (detected by fluorescence in situ hybridiza-
tion) had the greatest benefit from trastuzumab.70 The
median OS was 16 months [HR Z 0.65, 95% confidence in-
terval (CI) Z 0.51e0.83]. The sensitivity of EGFR-TKIs de-
pends on the primary-tumor location. Patients with gastric
cancer exhibit no activity with the therapy, whereas pa-
tients with the EGJ (Ade) tumors exhibit some activity after
the failure of surgery and radiotherapy.71,72 The efficacy of
therapy in these studies is not impressive, and research on
EGFR-TKI monotherapy in esophagogastric cancer is scant.
The only clinically approved targeted therapy is trastuzu-
mab, which targets the HER-2/NEU oncogene. However,
only a small group of patients with esophageal cancer
exhibit amplified HER-2. With the identification of other
essential targets and pathways, several other therapies are
anticipated for approval in the future.5.9. Predictive molecular markers of neoadjuvant
therapy in EGJ cancer
Patients with EGJ cancer are often treated with similar
therapies; however, they exhibit different outcomes. The
prognoses of patients who do not respond to trimodality
therapy strategies are inferior to those of patients who un-
dergo surgery. Moreover, trimodality therapy strategies can
result in significant undesirable consequences. The devel-
opment of validated predictive molecular markers can aid in
identifying patients who are more likely to be responders,
and in the selection of more efficient strategies involving a
tailored therapy. Predictive molecular markers for prevent-
ing expensive, noneffective, and potentially harmful thera-
pies must be investigated. Predictive markers are evaluated
through the clinical response to specific therapy, duration of
progression, and associated toxicity. Molecular markers can
be protein targets, such as growth factor receptors, angio-
genesis enzymes, cell-cycle regulators, gene expression
levels, and genetic variations in the tumor or host. However,
disease progression is greatly influenced by complex path-
ways, and the analysis of a single marker is insufficient for
predicting disease progression with reproducibility.
The predictive value of EGFR and HER-2/NEU messenger
RNA (mRNA) expression in E (Ade) tumors after neoadjuvant
CRT with cisplatin and 5-FU followed by transthoracic
esophagectomy is not associated with the degree of histo-
pathological response; the low intratumoral expression
levels of HER-2/NEU are significantly associated with pCR.73
The roles of p53 and survivin mRNA as predictive markers ofpCR in patients with locally advanced EGJ cancer who
received trimodality therapy are minor and inconsistent.74
Cyclooxygenase-2 (COX-2) is involved in the regulation of
tumor progression, angiogenesis, and resistance to
chemotherapy. High COX-2 expression is less sensitive to
neoadjuvant CRT, and has demonstrated an extremely poor
prognosis.75
The excision repair cross-complementing 1 (ERCC1) gene
encodes an enzyme required in the nucleotide excision
repair pathway. A more efficient DNA repair system may
lead to increased clinical resistance to a chemotherapeutic
agent. The overexpression of ERCC1 mRNA may indicate a
poor response to neoadjuvant chemotherapy.76 Gene
expression microarray profiling may be a powerful tool to
systematically search for the molecular markers of cancer
classification and outcome prediction. This is a potentially
valuable technology for separating patients with EGJ can-
cer sensitive to trimodality treatment regimens from those
who are resistant.77 The hypermethylation of the CpG is-
land methylator phenotype promoter is responsible for
silencing and inactivating the tumor suppressor gene. The
number of methylated genes per patient is significantly
lower in patients who experienced pCR compared with
those who did not.78
5.10. Radical surgery following induction
neoadjuvant therapy for Stage IV EGJ cancer
With the introduction of new chemotherapeutic regimens
and targeted agents, improved survival can be attained,
even for metastatic cases. Only a few studies have
compared tumor resection in Stage IV EGJ cancer with
palliative chemotherapy. Most studies have reported a
survival benefit from resection; however, this can be due to
a selection bias. Reevaluating the combination of chemo-
therapy with radical surgery in a large patient population
may lead to median survival times of 14.6e25.4 months,
with a remarkably low postoperative mortality.70,79 How-
ever, a complete tumor resection and histopathological
tumor regression remain two independent prognostic fac-
tors.80 Patients responding to chemotherapy have a greater
likelihood of R0 resection, which explains the use of
aggressive chemotherapy agents in palliative treatment.
5.11. Adjuvant therapy in EGJ cancer
Adjuvant chemotherapy in patients after esophagogas-
trectomy remains challenging. Common reasons for not
starting postoperative chemotherapy are disease progres-
sion or early death, patient choice, postoperative compli-
cations, and previous chemotherapy-related toxicity, as
reported in the MAGIC trial on a small patient population
completing adjuvant treatment.48 Surgery with post-
operative therapy presents potential advantages. The
removal of the primary tumor may help patients who did
not respond well to neoadjuvant therapy, or those with a
locally advanced tumor. In addition, adjuvant therapy can
add therapeutic effects until full surgical recovery is
ensured following neoadjuvant therapy and surgery.
Although a universally accepted standard treatment is un-
available for advanced-stage EGJ cancer, these treatments
194 P.-M. Huang, C.-N. Chenalone have been found to have a median survival of
9e12 months in randomized controlled trials.81 No signifi-
cant benefit has been found in 5-year OS after the addition
of adjuvant chemotherapy82 or adjuvant radiotherapy83 to
R0 resection; however, the studies were limited because of
their small samples.
The data necessary for the recommended use of adju-
vant chemotherapy for resected EGJ adenocarcinoma are
insufficient. Several studies have indicated that adjuvant
chemotherapy is poorly tolerated, with only 50% of patients
completing the planned postoperative therapy. Another
study reported that postoperative complications and mor-
tality rates were similar across all arms, and that the 5-year
survival rates improved significantly, from 23% to 36%.48
Data on the proportion of patients with EGJ (Ade) neces-
sary to measure the relevance to postoperative CRT are
lacking. An adjuvant CRT group and surgery alone or be-
tween histologic types exhibited similar outcomes. In
another study, the 5-year survival rate was similar across all
arms, and was influenced only by achieving the R0 resection
(32% vs. 5%, respectively, for lesser resections).84 The
Intergroup 0116 study investigated adjuvant CRT in 556
randomized patients with resected adenocarcinoma of the
stomach and EGJ (20%)85; 64% of patients completed the
planned treatment, and the 3-year OS was 50% in the CRT
group versus 41% in the surgery-only group (HRZ 1.35, 95%
CI Z 1.09e1.66, p Z 0.005). These data suggest that
adjuvant CRT should be considered for palliative treatment
or when surgical risks are high, whereas surgery alone re-
mains a potentially effective method that can cure patients
who cannot tolerate standard trimodality therapy.5.12. Further directions in the management of EGJ
cancer
Although diagnostic tools (e.g., endoscopic ultrasound) and
surgical skills (e.g., thoracoscopic and laparoscopic pro-
cedures) have been improved, the survival of patients with
EGJ cancer remains low. Type E (Sq or Ade) and EGJ (Sq or
Ade) tumors in this study were categorized as esophageal
cancer, in accordance with UICC/AJCC criteria; patients
with these tumors exhibited differences in clinicopatho-
logic characteristics. With an emphasis on EGJ tumors as a
well-defined entity, future studies are likely to provide
precise classification and optimal management. Current
chemotherapy regimens, although real, lead to minor im-
provements. Other agents are being investigated worldwide
for metastatic esophageal cancer and EGJ cancer, and
promising agents should be evaluated along with standard
neoadjuvant CRT. Recent research on the pathogenesis of
EGJ cancer, a brief review of the commonly known genetic
pathways in EGJ cancer, and the identification of new
genes with DNA microarray analysis will guide the devel-
opment of future therapies. The identification of molecular
marker subsets that can predict responses to multimodality
treatment strategies, the assessment of disease aggres-
siveness using prognostic markers, and the likelihood of
recurrence after surgery will assist clinicians in personal-
izing the combined modality treatment by optimizing drug
efficacy and minimizing adverse effects. The variables of
genetic polymorphisms in drug targets, metabolizingenzymes, transporters, and influential receptors are crucial
for analyzing drug efficacy.
The traditionally used CRT with platinum plus 5-FU may
be replaced with new regimens, including taxanes and iri-
notecan, which enable ease of prescription. Further data on
a comparison between chemotherapy and CRT are available
in the MAGIC versus CROSS trial (ClinicalTrials.gov identifier:
NCT01726452). HER-2 is currently the most well-established
target, based on the results of the ToGA trial,70 which
showed that the addition of trastuzumab to chemotherapy
improves OS in patients with advanced gastric or EGJ cancer.
The use of trastuzumab or other anti-HER-2 therapies in a
neoadjuvant or adjuvant setting is currently being evaluated
in various clinical trials (ClinicalTrials.gov identifiers:
NCT01748773, NCT01196390, and NCT00450203).6. Conclusion
A detailed preoperative staging and assessment of locore-
gional resectability and the exclusion of hepatic metastases
or peritoneal tumor spread are conducted using CT, PET,
and endoscopy in the staging of malignancies at the EGJ.
Early stage disease with no evidence of nodal spread and
invasion confined to the submucosa was found to have a
good prognosis, with complete local resection to ensure
negative margins, including lymph node dissection. Patients
with lymph node metastasis are required to confirm the
benefit of combined modality therapy, particularly because
celiac axis nodes are considered regional nodes, rather than
M1a metastasis. Extended lymphadenectomy in the lower
posterior mediastinum and the celiac area may improve the
prognosis of patients with a limited number of positive
lymph nodes. Certain long-term survival data for EGJ can-
cer have been summarized in this review, indicating the
necessity to improve the outcome using aggressive com-
bined modality therapy, particularly for patients with
advanced-stage cancer. Neoadjuvant chemotherapy is no
longer considered a standard approach for esophagogastric
SCC, and has been superseded by neoadjuvant or definitive
CRT. Neoadjuvant chemotherapy is an appropriate treat-
ment option for locally advanced esophagogastric adeno-
carcinoma, and evidence implies that CRT yields optimal
results. Definitive CRT is a valid treatment option for
resectable esophagogastric SCC, avoiding potential surgical
morbidity and mortality, with salvage surgery reserved for
those with persistent cancer or those noted with a tumor
relapse. However, neoadjuvant CRT followed by surgery is a
valid option for patients at lower surgical risk with no
comorbidities. Several surgical approaches are available,
however, additional data are required to select the most
appropriate approach for patients in R0 resection to lower
the risk of complications and improve the quality of life.References
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